Carboxylesterase 1(CES1), one of the most abundant serine hydrolases in mammals, has drawn much attentions in recent years, owing to this enzyme involves in many physiological processes via hydrolysis of both endogeno...Carboxylesterase 1(CES1), one of the most abundant serine hydrolases in mammals, has drawn much attentions in recent years, owing to this enzyme involves in many physiological processes via hydrolysis of both endogenous esters and xenobiotic esters. Herein, to real-time monitor the activities of CES1 in various biological systems, a practical and iso form-specific fluorescent probe was developed on the basis of the substrate preference of CES1, as well as the structural and optical properties of BODIPY dyes. After screening of a panel of BODIPY ester derivatives, probe 1 displayed the best combination of specificity,sensitivity, enzymatic kinetics and applicability for monitoring CES1 activities in real samples. This probe was successfully used to detect CESl activities in several biological systems including tissue preparations,living cells, tissue slices and zebrafish. Furthermore, the biomedical applications of probe 1 for screening of CES1 inhibitors were also demonstrated using tissue preparations or living cells as enzyme sources. In summary, a practical and broadly applicable tool for real-time monitoring CES1 in biological systems was developed and well-characterized, which held great promise for further investigations on CES1-associated drug discovery, clinical practice and fundamental research.展开更多
目的探讨ATP结合盒转运蛋白B1(ABCB1)及羧酸酯酶1(CES1)基因多态性与服用达比加群酯的患者药物谷浓度的相关性。方法选取2018年3月-2021年11月在福州某医院诊断为非瓣膜性房颤的69例患者作为研究对象。检测患者ABCB1及CES1的单核苷酸多...目的探讨ATP结合盒转运蛋白B1(ABCB1)及羧酸酯酶1(CES1)基因多态性与服用达比加群酯的患者药物谷浓度的相关性。方法选取2018年3月-2021年11月在福州某医院诊断为非瓣膜性房颤的69例患者作为研究对象。检测患者ABCB1及CES1的单核苷酸多态性位点以及基因型,采用抗Ⅱa因子显色法测定患者服用达比加群酯后药物的谷浓度,分析ABCB1及CES1基因多态性与谷浓度的相关性,进一步研究相关位点对谷浓度达标的影响。结果本研究共发现11个单核苷酸多态性位点,且ABCB1 rs2235013与ABCB1 rs2235033处于连锁不平衡状态(D’=0.96,r2=0.82)。但ABCB1基因多态性对达比加群谷浓度无显著影响(P>0.05)。CES1 rs2302719突变型(TG,GG)患者的达比加群谷浓度高于野生型(TT)(51.98±8.06 vs 42.44±3.88,57.71±9.06 vs 42.44±3.88),并且CES1 rs2302719突变型(TG,GG)是患者谷浓度达标的保护因素,结果具有统计学意义(P<0.05)。结论ABCB1基因多态性对达比加群谷浓度的影响还需进一步探索。CES1 rs2302719次要等位基因(G)可增加达比加群谷浓度,并且不良反应的发生率可能更低。展开更多
基金supported by the National Natural Science Foundation of China(Nos. 21572029, 31600641,81703604, 81773687, 81672961 and 81573501)the National Key Research and Development Program of China (Nos. 2017YFC1700200 and 2017YFC1702000)+2 种基金Program of Shanghai Academic/Technology Research Leader(No. 18XD1403600)Shuguang Program (No. 18SG40)supported by Shanghai Education Development Foundation and Shanghai Municipal Education Commission and the Innovative Entrepreneurship Program of High-level Talents in Dalian (Nos. 2016RQ025 and 2017RQ121)
文摘Carboxylesterase 1(CES1), one of the most abundant serine hydrolases in mammals, has drawn much attentions in recent years, owing to this enzyme involves in many physiological processes via hydrolysis of both endogenous esters and xenobiotic esters. Herein, to real-time monitor the activities of CES1 in various biological systems, a practical and iso form-specific fluorescent probe was developed on the basis of the substrate preference of CES1, as well as the structural and optical properties of BODIPY dyes. After screening of a panel of BODIPY ester derivatives, probe 1 displayed the best combination of specificity,sensitivity, enzymatic kinetics and applicability for monitoring CES1 activities in real samples. This probe was successfully used to detect CESl activities in several biological systems including tissue preparations,living cells, tissue slices and zebrafish. Furthermore, the biomedical applications of probe 1 for screening of CES1 inhibitors were also demonstrated using tissue preparations or living cells as enzyme sources. In summary, a practical and broadly applicable tool for real-time monitoring CES1 in biological systems was developed and well-characterized, which held great promise for further investigations on CES1-associated drug discovery, clinical practice and fundamental research.
文摘目的探讨ATP结合盒转运蛋白B1(ABCB1)及羧酸酯酶1(CES1)基因多态性与服用达比加群酯的患者药物谷浓度的相关性。方法选取2018年3月-2021年11月在福州某医院诊断为非瓣膜性房颤的69例患者作为研究对象。检测患者ABCB1及CES1的单核苷酸多态性位点以及基因型,采用抗Ⅱa因子显色法测定患者服用达比加群酯后药物的谷浓度,分析ABCB1及CES1基因多态性与谷浓度的相关性,进一步研究相关位点对谷浓度达标的影响。结果本研究共发现11个单核苷酸多态性位点,且ABCB1 rs2235013与ABCB1 rs2235033处于连锁不平衡状态(D’=0.96,r2=0.82)。但ABCB1基因多态性对达比加群谷浓度无显著影响(P>0.05)。CES1 rs2302719突变型(TG,GG)患者的达比加群谷浓度高于野生型(TT)(51.98±8.06 vs 42.44±3.88,57.71±9.06 vs 42.44±3.88),并且CES1 rs2302719突变型(TG,GG)是患者谷浓度达标的保护因素,结果具有统计学意义(P<0.05)。结论ABCB1基因多态性对达比加群谷浓度的影响还需进一步探索。CES1 rs2302719次要等位基因(G)可增加达比加群谷浓度,并且不良反应的发生率可能更低。
